Are you wanting to boost your portfolio with some blue chip ASX 200 shares in July?
Then you might want to look at the blue chips listed below. Here’s what you need to know about them:
Goodman Group (ASX: GMG)
The first blue chip ASX 200 share to look at is Goodman Group. It is a leading integrated commercial and industrial property company with a portfolio of warehouses, large scale logistics facilities, and business and office parks.
Goodman Group has been growing at a solid rate for years thanks to the success of its own+develop+manage model. This model sees Goodman own high quality properties, develop properties in key locations to meet customer needs, and manage the premium real estate it invests in globally.
When it comes to choosing properties, Goodman focuses on investing in and developing high quality industrial properties in strategic locations, close to large urban populations, and in and around major gateway cities globally. It notes that this is where demand is strong and transformational changes are driving significant opportunities for its business.
FY 2021 has been another year of growth for Goodman. Management recently revealed that it expects to achieve its guidance for operating profit of $1.2 billion and earnings per share growth of 12%.
Morgan Stanley is a fan of Goodman. It currently has a buy rating and $23.00 price target on its shares.
ResMed Inc. (ASX: RMD)
Another blue chip ASX 200 share to look at is ResMed. It is a medical device company with a focus on the sleep treatment market.
The sleep treatment market certainly is a great place to be. Management estimates that there are over 1 billion people globally that suffer from sleep apnoea. And with the vast majority of these people yet to be diagnosed, this gives ResMed a significant market opportunity to grow into.
And thanks to its industry-leading products, wide distribution network, and successful acquisitions, ResMed appears well-placed to capture this growing demand over the next decade.
In the near term, ResMed’s growth looks set to be boosted by the upcoming launch of its new CPAP device, AirSense 11, and a significant product recall by a leading rival.
Macquarie is positive on the company and current has an outperform rating and $34.85 price target on its shares.